Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
28 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-05-24
Study Completion Date
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is being done to answer the following questions:
* Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment?
* If there are specific biomarkers, do patients have an improved response to treatment compared to those without the biomarker?
This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for this type of cancer.
* Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment?
* If there are specific biomarkers, do patients have an improved response to treatment compared to those without the biomarker?
This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for this type of cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
NCT05147350
Advanced Solid Tumor
TERMINATED
PHASE1
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
NCT06509906
Advanced Solid Tumor
TERMINATED
PHASE1
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786
Colorectal Neoplasms
RECRUITING
PHASE3
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
NCT03635021
Colorectal Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
NCT05610163
Locally Advanced Rectal Carcinoma
Stage II Rectal Cancer AJCC v8
Stage III Rectal Cancer AJCC v8
ACTIVE_NOT_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
RP-6306 is a PKMYT1 inhibitor. PKMYT1 protein kinase negatively regulates CDK1 via phosphorylation of threonine 14 (Thr14) and sequestration in the cytoplasm. RP-6306 has shown single-agent anti-tumour efficacy in several xenograft models with amplified CCNE1 in a dose-dependent manner. RP-6306 has synergistic effects in combination with gemcitabine in CCNE1-amplified/overexpressing models in vitro and in vivo
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Advanced Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RP-6306 + Gemcitabine
Group Type
ACTIVE_COMPARATOR
RP-6306
Intervention Type
DRUG
Dose and schedule will be assigned at enrolment
Gemcitabine
Intervention Type
DRUG
Dose and schedule will be assigned at enrolment
RP-6306 + FOLFIRI
Group Type
ACTIVE_COMPARATOR
RP-6306
Intervention Type
DRUG
Dose and schedule will be assigned at enrolment
FOLFIRI Protocol
Intervention Type
DRUG
Irinotecan Leucovorin FU
RP-6306 + Trastuzumab
Group Type
ACTIVE_COMPARATOR
RP-6306
Intervention Type
DRUG
Dose and schedule will be assigned at enrolment
Trastuzumab
Intervention Type
DRUG
standard doses q3weekly
RP-6306 + RP-3500
Group Type
ACTIVE_COMPARATOR
RP-6306
Intervention Type
DRUG
Dose and schedule will be assigned at enrolment
RP-3500
Intervention Type
DRUG
Dose and schedule will be assigned at enrolment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RP-6306
Dose and schedule will be assigned at enrolment
Intervention Type
DRUG
Gemcitabine
Dose and schedule will be assigned at enrolment
Intervention Type
DRUG
FOLFIRI Protocol
Irinotecan Leucovorin FU
Intervention Type
DRUG
Trastuzumab
standard doses q3weekly
Intervention Type
DRUG
RP-3500
Dose and schedule will be assigned at enrolment
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Lunresertib
Camonsertib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have histologically confirmed cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists, and be eligible for one or more of the open cohorts
* All patients must have a formalin fixed paraffin embedded tissue block (from primary or metastatic tumour) available and must have provided informed consent for the release of the block
* Presence of clinically and/or radiologically documented disease. All radiology studies must be performed within 21 days prior to enrollment
* Patients must be ≥ 18 years of age
* Patients must have an ECOG performance status of 0 or 1
* Patients must have a life expectancy of 3 months or longer
* Hemoglobin ≥ 90 g/L (exceptions may be granted for well compensated and asymptomatic patients).
* Abs neutrophils ≥ 1.5 x 10\^9/L; Platelets ≥ 100 x 10\^9/L
* Bilirubin ≤ 1.5 x UNL; AST ≤2.5 x UNL; ALT ≤ 5.0 x UNL; Serum creatinine ≤ 1.5 x UNL; Creatinine clearance ≥ 50 mL/min
* Patients must be able to swallow oral medications and have no known gastrointestinal disorders that may interfere with absorption (such as malabsorption)
* Patients must have had recovered (to at least grade 0 or 1) from all reversible toxicity related to prior chemotherapy or systemic therapy and have adequate washout longest of one of the following: two weeks; 5 half-lives for investigational agents; standard cycle length of standard therapies.
* Prior external beam radiation is permitted provided a minimum of 28 days (4 weeks) have elapsed between the last dose of radiation and date of enrollment. Exceptions may be made for low-dose, non-myelosuppressive radiotherapy after consultation with CCTG. Concurrent radiotherapy is not permitted
* Previous surgery is permitted provided that a minimum of 21 days (3 weeks) have elapsed between any major surgery and date of enrollment, and that wound healing has occurred
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to screening (if applicable)/enrollment in the trial to document their willingness to participate
* Protocol treatment is to begin within 2 working days of patient enrollment
* Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre
* Women/men of childbearing potential must have agreed to use a highly effective contraceptive method.
Cohort-Specific Eligibility Criteria
Cohort A: Endometrial Cancer
* Patients must have histologically confirmed diagnosis of high-grade serous endometrial cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists.
* Patients must have abnormal TP53 on IHC/genomic testing\*.
* Patients must have had at least 1 prior line of platinum-based chemotherapy in any setting but may not have received prior gemcitabine therapy.
Cohort B1: HGSOC
* Patients must have a histologically confirmed diagnosis of high-grade serous ovarian cancer/fallopian tube/primary peritoneal carcinoma (HGSOC) which is platinum-refractory per standard definitions.
* Patients must have abnormal TP53 on IHC/genomic testing\*.
* Platinum refractory disease refers to patients with progressive disease on first-line platinum-based chemotherapy or progressive disease within 12 weeks of the last dose of first-line platinum-based therapy \[Gynecologic Cancer Intergroup Consensus Recommendations 2022\].
Cohort B2: Uterine Carcinosarcoma
* Patients must have had at least 1 prior line of platinum-based chemotherapy but may not have received prior gemcitabine therapy.
* Patients must have abnormal TP53 on IHC/genomic testing\*.
Cohort B3: Ovarian Carcinosarcoma
* Patients must have had at least 1 prior line of platinum-based chemotherapy but may not have received prior gemcitabine therapy.
* Patients must have abnormal TP53 on IHC/genomic testing\*.
Cohort B4: TNBC
* Patients must have had at least 2 prior lines of therapy in the advanced setting.
* Patients may not have received prior gemcitabine.
Cohort B5: PDAC
* Patients must have prior FOLFIRINOX either in the palliative/advanced setting or have relapsed within 6 months of completing adjuvant or neoadjuvant FOLFIRINOX.
* Patients may not have received prior gemcitabine.
* Patients must have abnormal TP53 on IHC/genomic testing\*.
Cohort B6: NSCLC
* Patients must have received standard therapies including platinum combination chemotherapy, standard salvage chemotherapy, immunotherapy, and targeted therapies as applicable.
* Patients may not have received prior gemcitabine.
Cohort C1: Colorectal Cancer
* Patients must have histologically confirmed diagnosis of colorectal cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists.
* Patients must have both a RAS mutation (KRAS) and a TP53 mutation based on local testing\*.
* Patients must be eligible to receive FOLFIRI; patients homozygous for UGT1A1\*28 allele are not eligible
* Patients must have had at least 1 prior line of cytotoxic chemotherapy with FOLFOX, either as:
* 1st line therapy for metastatic disease, or
* recurrence within 6 months of completion of adjuvant FOLFOX.
Cohort D1: HER-2+ Gastroesophageal Cancer
* Patients must have histologically confirmed diagnosis of gastroesophageal cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists.
* Tumour must be HER-2+ (IHC 3+, or FISH+) and have CCNE1 amplification
Cohort F1: Primary platinum refractory HGSOC
* Patients must have a histologically confirmed diagnosis of high grade serous ovarian cancer/fallopian tube/primary peritoneal carcinoma (HGSOC) which is platinum refractory per standard definitions.
* Patients must have one of the following for enrolment - Known CCNE1 amplification or deleterious mutations in either FBXW7 or PPP2R1A on local testing
\- Tumour designated as CCNE1 biomarker positive based on central testing (see Section 12.2)
* Platinum refractory disease refers to patients with progressive disease on first line platinum-based chemotherapy, or progressive disease within 12 weeks of the last dose of first line platinum-based therapy \[Gynecologic Cancer Intergroup Consensus Recommendations 2022\].
* All patients must have a formalin fixed paraffin embedded tissue block (from primary or metastatic tumour) available and must have provided informed consent for the release of the block
* Presence of clinically and/or radiologically documented disease. All radiology studies must be performed within 21 days prior to enrollment
* Patients must be ≥ 18 years of age
* Patients must have an ECOG performance status of 0 or 1
* Patients must have a life expectancy of 3 months or longer
* Hemoglobin ≥ 90 g/L (exceptions may be granted for well compensated and asymptomatic patients).
* Abs neutrophils ≥ 1.5 x 10\^9/L; Platelets ≥ 100 x 10\^9/L
* Bilirubin ≤ 1.5 x UNL; AST ≤2.5 x UNL; ALT ≤ 5.0 x UNL; Serum creatinine ≤ 1.5 x UNL; Creatinine clearance ≥ 50 mL/min
* Patients must be able to swallow oral medications and have no known gastrointestinal disorders that may interfere with absorption (such as malabsorption)
* Patients must have had recovered (to at least grade 0 or 1) from all reversible toxicity related to prior chemotherapy or systemic therapy and have adequate washout longest of one of the following: two weeks; 5 half-lives for investigational agents; standard cycle length of standard therapies.
* Prior external beam radiation is permitted provided a minimum of 28 days (4 weeks) have elapsed between the last dose of radiation and date of enrollment. Exceptions may be made for low-dose, non-myelosuppressive radiotherapy after consultation with CCTG. Concurrent radiotherapy is not permitted
* Previous surgery is permitted provided that a minimum of 21 days (3 weeks) have elapsed between any major surgery and date of enrollment, and that wound healing has occurred
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to screening (if applicable)/enrollment in the trial to document their willingness to participate
* Protocol treatment is to begin within 2 working days of patient enrollment
* Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre
* Women/men of childbearing potential must have agreed to use a highly effective contraceptive method.
Cohort-Specific Eligibility Criteria
Cohort A: Endometrial Cancer
* Patients must have histologically confirmed diagnosis of high-grade serous endometrial cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists.
* Patients must have abnormal TP53 on IHC/genomic testing\*.
* Patients must have had at least 1 prior line of platinum-based chemotherapy in any setting but may not have received prior gemcitabine therapy.
Cohort B1: HGSOC
* Patients must have a histologically confirmed diagnosis of high-grade serous ovarian cancer/fallopian tube/primary peritoneal carcinoma (HGSOC) which is platinum-refractory per standard definitions.
* Patients must have abnormal TP53 on IHC/genomic testing\*.
* Platinum refractory disease refers to patients with progressive disease on first-line platinum-based chemotherapy or progressive disease within 12 weeks of the last dose of first-line platinum-based therapy \[Gynecologic Cancer Intergroup Consensus Recommendations 2022\].
Cohort B2: Uterine Carcinosarcoma
* Patients must have had at least 1 prior line of platinum-based chemotherapy but may not have received prior gemcitabine therapy.
* Patients must have abnormal TP53 on IHC/genomic testing\*.
Cohort B3: Ovarian Carcinosarcoma
* Patients must have had at least 1 prior line of platinum-based chemotherapy but may not have received prior gemcitabine therapy.
* Patients must have abnormal TP53 on IHC/genomic testing\*.
Cohort B4: TNBC
* Patients must have had at least 2 prior lines of therapy in the advanced setting.
* Patients may not have received prior gemcitabine.
Cohort B5: PDAC
* Patients must have prior FOLFIRINOX either in the palliative/advanced setting or have relapsed within 6 months of completing adjuvant or neoadjuvant FOLFIRINOX.
* Patients may not have received prior gemcitabine.
* Patients must have abnormal TP53 on IHC/genomic testing\*.
Cohort B6: NSCLC
* Patients must have received standard therapies including platinum combination chemotherapy, standard salvage chemotherapy, immunotherapy, and targeted therapies as applicable.
* Patients may not have received prior gemcitabine.
Cohort C1: Colorectal Cancer
* Patients must have histologically confirmed diagnosis of colorectal cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists.
* Patients must have both a RAS mutation (KRAS) and a TP53 mutation based on local testing\*.
* Patients must be eligible to receive FOLFIRI; patients homozygous for UGT1A1\*28 allele are not eligible
* Patients must have had at least 1 prior line of cytotoxic chemotherapy with FOLFOX, either as:
* 1st line therapy for metastatic disease, or
* recurrence within 6 months of completion of adjuvant FOLFOX.
Cohort D1: HER-2+ Gastroesophageal Cancer
* Patients must have histologically confirmed diagnosis of gastroesophageal cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists.
* Tumour must be HER-2+ (IHC 3+, or FISH+) and have CCNE1 amplification
Cohort F1: Primary platinum refractory HGSOC
* Patients must have a histologically confirmed diagnosis of high grade serous ovarian cancer/fallopian tube/primary peritoneal carcinoma (HGSOC) which is platinum refractory per standard definitions.
* Patients must have one of the following for enrolment - Known CCNE1 amplification or deleterious mutations in either FBXW7 or PPP2R1A on local testing
\- Tumour designated as CCNE1 biomarker positive based on central testing (see Section 12.2)
* Platinum refractory disease refers to patients with progressive disease on first line platinum-based chemotherapy, or progressive disease within 12 weeks of the last dose of first line platinum-based therapy \[Gynecologic Cancer Intergroup Consensus Recommendations 2022\].
Exclusion Criteria
* Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for \> 2 years and which do not require ongoing treatment
* Patients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol
* Patients are not eligible if they have a known hypersensitivity to the study drug(s) or their components
* Prior use of WEE1 inhibitor or PKMYT1 inhibitor
* Patients with significant cardiac (including uncontrolled hypertension) or pulmonary disease, or active CNS disease or infection. Patients should have a LVEF ≥ 50%.
* Patients may not receive concurrent treatment with other anti-cancer therapy (other than bone-targeted therapy, if already taking and stable) or investigational agents while on protocol therapy
* Patients who have received growth factors within 28 days prior to initiation of dosing of RP-6306 or who will require treatment with growth factors throughout the duration of the trial
* Pregnant or breastfeeding women
* Patients with history of central nervous system metastases or spinal cord compression unless they have received definitive treatment, are clinically stable and do not require corticosteroids
* Patients with any medical condition that would impair the administration of oral agents including significant bowel resection, inflammatory bowel disease or uncontrolled nausea or vomiting
* Patients who cannot discontinue the use of proton pump inhibitors, strong CYP3A inhibitors or inducers.
* Patients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol
* Patients are not eligible if they have a known hypersensitivity to the study drug(s) or their components
* Prior use of WEE1 inhibitor or PKMYT1 inhibitor
* Patients with significant cardiac (including uncontrolled hypertension) or pulmonary disease, or active CNS disease or infection. Patients should have a LVEF ≥ 50%.
* Patients may not receive concurrent treatment with other anti-cancer therapy (other than bone-targeted therapy, if already taking and stable) or investigational agents while on protocol therapy
* Patients who have received growth factors within 28 days prior to initiation of dosing of RP-6306 or who will require treatment with growth factors throughout the duration of the trial
* Pregnant or breastfeeding women
* Patients with history of central nervous system metastases or spinal cord compression unless they have received definitive treatment, are clinically stable and do not require corticosteroids
* Patients with any medical condition that would impair the administration of oral agents including significant bowel resection, inflammatory bowel disease or uncontrolled nausea or vomiting
* Patients who cannot discontinue the use of proton pump inhibitors, strong CYP3A inhibitors or inducers.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Repare Therapeutics
INDUSTRY
Sponsor Role
collaborator
Canadian Cancer Trials Group
NETWORK
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephanie Lheureux
Role: STUDY_CHAIR
University Health Network, Princess Margaret Hospital, Toronto ON Canada
Yvette Drew
Role: STUDY_CHAIR
BCCA-Vancouver Cancer Centre, Vancouver BC Canada
Eric Chen
Role: STUDY_CHAIR
University Health Network, Princess Margaret Hospital, Toronto ON Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BCCA - Kelowna
Kelowna, British Columbia, Canada
Site Status
BCCA - Vancouver
Vancouver, British Columbia, Canada
Site Status
Kingston Health Sciences Centre
Kingston, Ontario, Canada
Site Status
London Health Sciences Centre Research Inc.
London, Ontario, Canada
Site Status
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Site Status
University Health Network
Toronto, Ontario, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I243
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490
RECRUITING
PHASE3
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
NCT05360732
ACTIVE_NOT_RECRUITING
PHASE2
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
NCT04511039
RECRUITING
PHASE1
Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer
NCT04450836
TERMINATED
PHASE2
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649
RECRUITING
PHASE3
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
NCT03783936
COMPLETED
PHASE2
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
NCT05476796
RECRUITING
PHASE2
Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer
NCT00786006
COMPLETED
PHASE2
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
NCT00101894
COMPLETED
PHASE1
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
NCT00138177
COMPLETED
PHASE1
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
NCT03699319
COMPLETED
PHASE1/PHASE2
FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma
NCT03528876
TERMINATED
PHASE2
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
NCT01326000
COMPLETED
PHASE2
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
NCT00615056
COMPLETED
PHASE2
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation
NCT03584711
COMPLETED
PHASE2
Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer
NCT02705300
COMPLETED
PHASE2
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
NCT01688336
TERMINATED
PHASE2
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
NCT00004059
COMPLETED
PHASE1
A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
NCT05945901
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
NCT01289821
COMPLETED
PHASE2
Study Evaluating EKB-569 in Advanced Colorectal Cancer
NCT00072748
COMPLETED
PHASE2
Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer
NCT00291785
COMPLETED
PHASE1/PHASE2
RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).
NCT02280070
UNKNOWN
PHASE2
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
NCT00339183
COMPLETED
PHASE3